Takeda Pharmaceutical (NYSE:TAK) Stock Rating Upgraded by Zacks Research

Takeda Pharmaceutical (NYSE:TAK) was upgraded by research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued on Tuesday,Zacks.com reports.

A number of other equities analysts have also recently commented on TAK. Wall Street Zen raised Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a report on Saturday, July 18th. Weiss Ratings lowered Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, July 30th. Finally, Sanford C. Bernstein upgraded Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a research report on Wednesday, April 8th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Takeda Pharmaceutical presently has a consensus rating of “Hold”.

Takeda Pharmaceutical Stock Performance

Shares of NYSE:TAK opened at $16.72 on Tuesday. Takeda Pharmaceutical has a 1 year low of $12.99 and a 1 year high of $18.90. The stock has a market capitalization of $53.57 billion, a price-to-earnings ratio of 49.17 and a beta of -0.08. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.14 and a quick ratio of 0.60. The company’s 50 day simple moving average is $16.30 and its 200 day simple moving average is $17.09.

Takeda Pharmaceutical (NYSE:TAK) last released its earnings results on Tuesday, March 31st. The company reported $0.56 earnings per share for the quarter. The firm had revenue of $6.90 billion during the quarter. Takeda Pharmaceutical had a return on equity of 10.95% and a net margin of 3.80%. As a group, research analysts predict that Takeda Pharmaceutical will post 3.01 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Private Trust Co. NA boosted its holdings in shares of Takeda Pharmaceutical by 84.7% during the 4th quarter. Private Trust Co. NA now owns 1,707 shares of the company’s stock valued at $27,000 after acquiring an additional 783 shares in the last quarter. Parkside Financial Bank & Trust increased its holdings in Takeda Pharmaceutical by 192.2% in the 4th quarter. Parkside Financial Bank & Trust now owns 2,560 shares of the company’s stock worth $40,000 after purchasing an additional 1,684 shares in the last quarter. SHP Wealth Management bought a new position in Takeda Pharmaceutical in the fourth quarter valued at about $42,000. Caitong International Asset Management Co. Ltd raised its position in Takeda Pharmaceutical by 313.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,070 shares of the company’s stock valued at $48,000 after purchasing an additional 2,328 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. raised its position in Takeda Pharmaceutical by 56.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company’s stock valued at $55,000 after purchasing an additional 1,292 shares during the last quarter. 9.17% of the stock is currently owned by institutional investors and hedge funds.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.